Impact of pre‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial

Prior studies have suggested that patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR) are at higher risk for adverse cardiovascular events. Whether procedural bivalirudin compared with unfractionated heparin (UFH) has a beneficial effect on early outcomes in these patients is unknown. We examined for the effect of baseline or new‐onset AF within 30 days of TAVR and explored for the effect of bivalirudin versus UFH by AF status, on 30‐day outcomes from the BRAVO 3 trial.

[1]  Wen Cheng,et al.  Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study , 2017, The Lancet.

[2]  B. Cave,et al.  Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. , 2017, JACC. Cardiovascular interventions.

[3]  J. Tijssen,et al.  Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study , 2017, American heart journal.

[4]  G. Dangas,et al.  Cerebral Embolic Protection During TAVR: A Clinical Event Meta-Analysis. , 2017, Journal of the American College of Cardiology.

[5]  E. Tuzcu,et al.  Atrial Fibrillation and Transcatheter Aortic Valve Replacement: Implications of Pre-Procedural Identification of Left Atrial Appendage Thrombus for Stroke Prevention. , 2017, JACC. Cardiovascular interventions.

[6]  W. Rottbauer,et al.  Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. , 2017, JACC. Cardiovascular interventions.

[7]  G. Tarantini,et al.  Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome , 2016, European heart journal.

[8]  M. Mack,et al.  Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter Valves) , 2016, Circulation. Cardiovascular interventions.

[9]  A. Regueiro,et al.  Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.

[10]  C. Hengstenberg,et al.  Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study. , 2016, Journal of the American College of Cardiology.

[11]  G. Gerosa,et al.  Prevalence and Impact of Atrial Fibrillation in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the SOURCE XT Prospective Multicenter Registry. , 2016, JACC. Cardiovascular interventions.

[12]  B. Gersh,et al.  Atrial Fibrillation Post-Transcatheter Aortic Valve Replacement: Cause, Consequence, or Confounder? , 2016, JACC. Cardiovascular interventions.

[13]  R. Kornowski,et al.  Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement , 2016, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[14]  P. Stella,et al.  Incidence, Predictive Factors, and Effect of Delirium After Transcatheter Aortic Valve Replacement. , 2016, JACC. Cardiovascular interventions.

[15]  M. Mack,et al.  Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial , 2016, Circulation. Cardiovascular interventions.

[16]  C. Hengstenberg,et al.  Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. , 2015, Journal of the American College of Cardiology.

[17]  Deepak L. Bhatt,et al.  Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. , 2015, The New England journal of medicine.

[18]  P. Wenaweser,et al.  The Incidence and Predictors of Early- and Mid-Term Clinically Relevant Neurological Events After Transcatheter Aortic Valve Replacement in Real-World Patients. , 2015, Journal of the American College of Cardiology.

[19]  H. Huikuri,et al.  Electrocardiographic patch devices and contemporary wireless cardiac monitoring , 2015, Front. Physiol..

[20]  A. Kappetein,et al.  Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. , 2015, JACC. Cardiovascular interventions.

[21]  I. Barbash,et al.  Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[22]  G. Breithardt,et al.  Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial , 2014, European heart journal.

[23]  G. Eslick,et al.  Transcatheter versus surgical aortic valve replacement: a systematic review and meta-analysis of randomised and non-randomised trials , 2014, Open Heart.

[24]  J. Mega,et al.  Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. , 2013, Journal of the American College of Cardiology.

[25]  W. O’Neill,et al.  New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. , 2013, Journal of the American College of Cardiology.

[26]  A. Kirtane,et al.  Stroke associated with surgical and transcatheter treatment of aortic stenosis: a comprehensive review. , 2011, Journal of the American College of Cardiology.

[27]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[28]  S. Susen,et al.  Identification of tissue factor in experimental aortic valve sclerosis. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[29]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[30]  A. Waldo.  Stroke prevention in atrial fibrillation. , 2003, JAMA.

[31]  E. Erdmann,et al.  Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. , 2012, The Annals of thoracic surgery.